Loading patent…
AssigneeMagenta Therapeutics, Inc.
InventorsAndrew NIXON, Dwight MORROW, Adam HARTIGAN
Estimating the term…
The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.
1-112. (canceled)
A method of depleting a population of CD117+ cells in a human patient, the method comprising administering an effective amount of a conjugate comprising an anti-CD117 antibody, or an antigen-binding fragment thereof, and an amatoxin, wherein the antibody, or the antigen-binding fragment thereof, is internalized by a CD117+ cell, and wherein the patient does not have an immunodeficiency disorder.
A method of conditioning a human patient for receiving a hematopoietic stem cell (HSC) transplantation, said method comprising
Dependencies are inferred from the claim text.